BAIA
BMRN icon

Bel Air Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bel Air Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$803K Hold
9,619
– – 0.02% 201
2021
Q1 		$726K Buy
+9,619
New +$786K 0.02% 229

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bel Air Investment Advisors's BMRN Position: Q2 2021 in Review

Bel Air Investment Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2021 at 9,619 shares worth $803K. The position accounts for 0.02% of the portfolio, ranked #201.

Bel Air Investment Advisors first reported a position in BMRN in Q1 2021 and has held it in 2 quarters since. 530 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

  • Bel Air Investment Advisors held 9,619 shares of BioMarin Pharmaceuticals worth $803K as of Q2 2021.
  • Bel Air Investment Advisors left its BioMarin Pharmaceuticals share count unchanged in Q2 2021.
  • BioMarin Pharmaceuticals made up 0.02% of Bel Air Investment Advisors's portfolio in Q2 2021, its #201 holding.
  • Bel Air Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
  • 530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on Bel Air Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.